BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 17880451)

  • 1. European study on orthopaedic status of haemophilia patients with inhibitors.
    Morfini M; Haya S; Tagariello G; Pollmann H; Quintana M; Siegmund B; Stieltjes N; Dolan G; Tusell J
    Haemophilia; 2007 Sep; 13(5):606-12. PubMed ID: 17880451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Articular status of haemophilia patients with inhibitors.
    Morfini M
    Haemophilia; 2008 Nov; 14 Suppl 6():20-2. PubMed ID: 19134029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESOS: a European study on the orthopaedic status of patients with haemophilia and inhibitors.
    Dolan G
    Haemophilia; 2005 Nov; 11 Suppl 1():24-5. PubMed ID: 16219046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors.
    Scalone L; Mantovani LG; Mannucci PM; Gringeri A;
    Haemophilia; 2006 Mar; 12(2):154-62. PubMed ID: 16476090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients).
    Rodriguez-Merchan EC; Quintana M; Jimenez-Yuste V; Hernández-Navarro F
    Haemophilia; 2007 Sep; 13(5):613-9. PubMed ID: 17880452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of rehabilitation and sports in haemophilia patients with inhibitors.
    Heijnen L
    Haemophilia; 2008 Nov; 14 Suppl 6():45-51. PubMed ID: 19134033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
    Khawaji M; Astermark J; Berntorp E
    Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
    Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
    Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemophilia in Poland.
    Windyga J; Lopaciuk S; Stefanska E; Juszynski A; Wozniak D; Strzelecki O; Szczepanik AB
    Haemophilia; 2006 Jan; 12(1):52-7. PubMed ID: 16409175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
    Ullman M; Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M; Warrier I; Rajpurkar M; Lusher JM
    Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.